Corvus Pharmaceuticals, Inc.

NasdaqGM CRVS

Corvus Pharmaceuticals, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Corvus Pharmaceuticals, Inc. EBT Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqGM: CRVS

Corvus Pharmaceuticals, Inc.

CEO	Dr. Richard A. Miller M.D.
IPO Date	March 23, 2016
Location	United States
Headquarters	863 Mitten Road
Employees	28
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Composite Materials Drugstores & Retail Pharmacies Tobacco Vaccines

Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Key trends

Past 5 years